Cargando…

IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic cancer has been a threateningly lethal malignant tumor worldwide. Despite the promising survival improvement in other cancer types attributing to the fast development of molecular precise medicine, the current treatment situation of pancreatic cancer is still woefully challeng...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Rong, Qi, Guoye, Zeng, Zixin, Shen, Ningning, Wang, Ziyue, Shen, Honghong, Gao, Lifang, Song, Chen, Ma, Wenxia, Wang, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613923/
https://www.ncbi.nlm.nih.gov/pubmed/34819098
http://dx.doi.org/10.1186/s12935-021-02324-w
_version_ 1784603747185328128
author Wei, Rong
Qi, Guoye
Zeng, Zixin
Shen, Ningning
Wang, Ziyue
Shen, Honghong
Gao, Lifang
Song, Chen
Ma, Wenxia
Wang, Chen
author_facet Wei, Rong
Qi, Guoye
Zeng, Zixin
Shen, Ningning
Wang, Ziyue
Shen, Honghong
Gao, Lifang
Song, Chen
Ma, Wenxia
Wang, Chen
author_sort Wei, Rong
collection PubMed
description BACKGROUND: Pancreatic cancer has been a threateningly lethal malignant tumor worldwide. Despite the promising survival improvement in other cancer types attributing to the fast development of molecular precise medicine, the current treatment situation of pancreatic cancer is still woefully challenging since its limited response to neither traditional radiotherapy and chemotherapy nor emerging immunotherapy. The study is to explore potential responsible genes during the development of pancreatic cancer, thus identifying promising gene indicators and probable drug targets. METHODS: Different bioinformatic analysis were used to interpret the genetic events in pancreatic cancer development. Firstly, based on multiple cDNA microarray profiles from Gene Expression Omnibus (GEO) database, the genes with differently mRNA expression in cancer comparing to normal pancreatic tissues were identified, followed by being grouped based on the difference level. Then, GO and KEGG were performed to separately interpret the multiple groups of genes, and further Kaplan–Meier survival and Cox Regression analysis assisted us to scale down the candidate genes and select the potential key genes. Further, the basic physicochemical properties, the association with immune cells infiltration, mutation or other types variations besides expression gap in pancreatic cancer comparing to normal tissues of the selected key genes were analyzed. Moreover, the aberrant changed expression of key genes was validated by immunohistochemistry (IHC) experiment using local hospital tissue microarray samples and the clinical significance was explored based on TCGA clinical data. RESULTS: Firstly, a total of 22,491 genes were identified to express differently in cancer comparing to normal pancreatic tissues based on 5 cDNA expression profiles, and the difference of 487/22491 genes was over eightfold, and 55/487 genes were shared in multi profiles. Moreover, after genes interpretation which showed the > eightfold genes were mainly related to extracellular matrix structural constituent regulation, Kaplan–Meier survival and Cox-regression analysis were performed continually, and the result indicated that of the 55 extracellular locating genes, GPRC5A and IMUP were the only two independent prognostic indicators of pancreatic cancer. Further, detailed information of IMUP and GPRC5A were analyzed including their physicochemical properties, their expression and variation ratio and their association with immune cells infiltration in cancer, as well as the probable signaling pathways of genes regulation on pancreatic cancer development. Lastly, local IHC experiment performed on PAAD tissue array which was produced with 62 local hospital patients samples confirmed that GPRC5A and IMUP were abnormally up-regulated in pancreatic cancer, which directly associated with worse patients both overall (OS) and recurrence free survival (RFS). CONCLUSIONS: Using multiple bioinformatic analysis as well as local hospital samples validation, we revealed that GPRC5A and IMUP expression were abnormally up-regulated in pancreatic cancer which associated statistical significantly with patients survival, and the genes’ biological features and clinical significance were also explored. However, more detailed experiments and clinical trials are obligatory to support their further potential drug-target role in clinical medical treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02324-w.
format Online
Article
Text
id pubmed-8613923
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86139232021-11-29 IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma Wei, Rong Qi, Guoye Zeng, Zixin Shen, Ningning Wang, Ziyue Shen, Honghong Gao, Lifang Song, Chen Ma, Wenxia Wang, Chen Cancer Cell Int Primary Research BACKGROUND: Pancreatic cancer has been a threateningly lethal malignant tumor worldwide. Despite the promising survival improvement in other cancer types attributing to the fast development of molecular precise medicine, the current treatment situation of pancreatic cancer is still woefully challenging since its limited response to neither traditional radiotherapy and chemotherapy nor emerging immunotherapy. The study is to explore potential responsible genes during the development of pancreatic cancer, thus identifying promising gene indicators and probable drug targets. METHODS: Different bioinformatic analysis were used to interpret the genetic events in pancreatic cancer development. Firstly, based on multiple cDNA microarray profiles from Gene Expression Omnibus (GEO) database, the genes with differently mRNA expression in cancer comparing to normal pancreatic tissues were identified, followed by being grouped based on the difference level. Then, GO and KEGG were performed to separately interpret the multiple groups of genes, and further Kaplan–Meier survival and Cox Regression analysis assisted us to scale down the candidate genes and select the potential key genes. Further, the basic physicochemical properties, the association with immune cells infiltration, mutation or other types variations besides expression gap in pancreatic cancer comparing to normal tissues of the selected key genes were analyzed. Moreover, the aberrant changed expression of key genes was validated by immunohistochemistry (IHC) experiment using local hospital tissue microarray samples and the clinical significance was explored based on TCGA clinical data. RESULTS: Firstly, a total of 22,491 genes were identified to express differently in cancer comparing to normal pancreatic tissues based on 5 cDNA expression profiles, and the difference of 487/22491 genes was over eightfold, and 55/487 genes were shared in multi profiles. Moreover, after genes interpretation which showed the > eightfold genes were mainly related to extracellular matrix structural constituent regulation, Kaplan–Meier survival and Cox-regression analysis were performed continually, and the result indicated that of the 55 extracellular locating genes, GPRC5A and IMUP were the only two independent prognostic indicators of pancreatic cancer. Further, detailed information of IMUP and GPRC5A were analyzed including their physicochemical properties, their expression and variation ratio and their association with immune cells infiltration in cancer, as well as the probable signaling pathways of genes regulation on pancreatic cancer development. Lastly, local IHC experiment performed on PAAD tissue array which was produced with 62 local hospital patients samples confirmed that GPRC5A and IMUP were abnormally up-regulated in pancreatic cancer, which directly associated with worse patients both overall (OS) and recurrence free survival (RFS). CONCLUSIONS: Using multiple bioinformatic analysis as well as local hospital samples validation, we revealed that GPRC5A and IMUP expression were abnormally up-regulated in pancreatic cancer which associated statistical significantly with patients survival, and the genes’ biological features and clinical significance were also explored. However, more detailed experiments and clinical trials are obligatory to support their further potential drug-target role in clinical medical treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02324-w. BioMed Central 2021-11-24 /pmc/articles/PMC8613923/ /pubmed/34819098 http://dx.doi.org/10.1186/s12935-021-02324-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Primary Research
Wei, Rong
Qi, Guoye
Zeng, Zixin
Shen, Ningning
Wang, Ziyue
Shen, Honghong
Gao, Lifang
Song, Chen
Ma, Wenxia
Wang, Chen
IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma
title IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma
title_full IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma
title_fullStr IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma
title_full_unstemmed IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma
title_short IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma
title_sort imup and gprc5a: two newly identified risk score indicators in pancreatic ductal adenocarcinoma
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613923/
https://www.ncbi.nlm.nih.gov/pubmed/34819098
http://dx.doi.org/10.1186/s12935-021-02324-w
work_keys_str_mv AT weirong imupandgprc5atwonewlyidentifiedriskscoreindicatorsinpancreaticductaladenocarcinoma
AT qiguoye imupandgprc5atwonewlyidentifiedriskscoreindicatorsinpancreaticductaladenocarcinoma
AT zengzixin imupandgprc5atwonewlyidentifiedriskscoreindicatorsinpancreaticductaladenocarcinoma
AT shenningning imupandgprc5atwonewlyidentifiedriskscoreindicatorsinpancreaticductaladenocarcinoma
AT wangziyue imupandgprc5atwonewlyidentifiedriskscoreindicatorsinpancreaticductaladenocarcinoma
AT shenhonghong imupandgprc5atwonewlyidentifiedriskscoreindicatorsinpancreaticductaladenocarcinoma
AT gaolifang imupandgprc5atwonewlyidentifiedriskscoreindicatorsinpancreaticductaladenocarcinoma
AT songchen imupandgprc5atwonewlyidentifiedriskscoreindicatorsinpancreaticductaladenocarcinoma
AT mawenxia imupandgprc5atwonewlyidentifiedriskscoreindicatorsinpancreaticductaladenocarcinoma
AT wangchen imupandgprc5atwonewlyidentifiedriskscoreindicatorsinpancreaticductaladenocarcinoma